TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| ARIAD Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript ARIAD Pharmaceuticals, Inc. (ARIA)Q1 2010 Earnings Call TranscriptMay 10, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Malaria's Tenacious Buzz Even as the fight against malaria gains momentum, research reveals that malaria's tentacles continue to dig ever deeper. online.wsj.com |
Merck's Profit Falls 52% Pharmaceutical giant Merck said its earnings dropped 52%, weighed down by acquisition and other charges and weaker sales of key drugs. online.wsj.com |
Feds Intervene in Pfizer Suit Over Illegal Drug Promotion Pharmalot submits: Four months after two sales reps caused a sensation by charging that Wyeth (WYE) illegally promoted its Rapamune kidney transplant drug for use with other organs and targeted African-Americans, the federal government has filed a motion with a federal court to intervene, or join their whistleblower lawsuit. In a document (pdf) filed Tuesday in US District Court in Philadelphia, the US Attorney for Pennsylvania and 19 states, along with the District of Columbia, wrote that “the United States has established good cause to intervene…” An accompanying memorandum, however, was filed separately under seal. Wyeth, by the way, is now part of Pfizer (PFE).Complete Story » seekingalpha.com |
ImmunoCellular Therapeutics CEO Explains Economic Significance of New Vaccine Manufacturing Method M.E. Garza submits: On Wednesday morning, ImmunoCellular Therapeutics (IMUC.OB) announced that it has developed an innovative method for manufacturing the company’s dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM). Given all the headlines that Dendreon (Nasdaq:DNDN) has made with its manufacturing problems, IMUC's lead product candidate, ICT-107, may well start making news of its own. DNDN's Provenge won FDA approval last April, but sales have been hindered by the company's limited production capacity, an issue which DNDN management has said it expects to resolve some time next year.Complete Story » seekingalpha.com |